MethylGene to Reincorporate in US, List on NASDAQ
Posted on: May 9, 2013 by Kirk FalconerNo Comments »
Montréal-based MethylGene Inc., a publicly-traded, venture-backed biopharmaceuticals company, has proposed reincorporating in the state of Delaware under a new parent organization called Mirati Therapeutics Inc. As part of the arrangement, Mirati will apply to list shares on NASDAQ. The plan, to be approved by shareholders in June, seeks to increase Methylgene’s financing options and profile in the United States, among other factors. The company’s investors include several Canadian and U.S. venture capital firms, including Baker Brothers, BDC Venture Capital, Fonds de solidarité des travailleurs du Québec (FTQ), GeneChem, OriMed Advisors, ProQuest Investments, Tang Capital and Tavistock Life Sciences.
